Core Viewpoint - Align Technology, Inc. has announced the commercial availability of the Invisalign System with mandibular advancement in the Philippines, targeting Class II skeletal and dental issues [1] Company Overview - Align Technology, Inc. is a leading global medical device company specializing in the design, manufacture, and sale of the Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry [1]

Core Insights - Artificial intelligence (AI) has surpassed human analysts in accurately identifying customer needs, with a fine-tuned model achieving 100% detection compared to 87.5% by human analysts [2] - Companies are increasingly integrating AI into their workflows for customer feedback processing, leading to a shift from centralized analysis to day-to-day operations [3] AI Integration in Workflows - Oracle has introduced AI agents for sales that utilize multilingual data to generate account summaries and insight reports, aiming to embed AI into sales processes [4] - Clorox is implementing generative AI tools in its product development and consumer feedback processes as part of a $580 million digital transformation plan, analyzing customer reviews to identify emerging themes [5] - Companies using AI for customer interactions have seen up to a 45% increase in customer satisfaction and a 30% reduction in operational costs due to improved issue detection and request routing [5] Expansion of AI-Driven Analysis - AI systems are increasingly handling initial customer-signal processing across various functions, including sales, service, marketing, and product operations [6] - Vercel has deployed AI agents trained on top sales personnel to qualify leads and filter inquiries, consolidating tasks that previously required multiple employees [7] AI in Product Development - The use of AI has extended into product development, where it processes signals that inform decisions on ingredients and product formulas [9] - Barry Callebaut partnered with NotCo to utilize AI for generating new chocolate formulations, analyzing ingredient alternatives and consumer preferences [10] - Johnson & Johnson has redirected its AI efforts towards product and research workflows, reporting that 10% to 15% of initial projects yielded significant results [11]

Core Points - GE HealthCare Technologies Inc. declared a cash dividend of $0.035 per share for the fourth quarter of 2025, payable on February 13, 2026, to shareholders of record as of January 9, 2026 [1] - GE HealthCare is a leading global healthcare solutions provider with a focus on medical technology, pharmaceutical diagnostics, and AI-enabled solutions, generating approximately $19.7 billion in revenue and employing around 53,000 people [2] - The company aims to enhance healthcare efficiency and patient outcomes through its various business segments, including Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics [2] Company Overview - GE HealthCare has been a trusted partner in healthcare for over 125 years, focusing on personalized and connected care while simplifying patient journeys [2] - The company is recognized as one of the 2025 Fortune World's Most Admired Companies [3] Recent Developments - GE HealthCare announced the acquisition of Intelerad, a medical imaging software provider, for $2.3 billion in cash, which aligns with its strategy to enhance cloud-enabled and AI-powered solutions [6] - The company is committed to tripling its offerings of cloud-enabled products by 2028 [6] - GE HealthCare management will present at the Jefferies Global Healthcare Conference on November 18, 2025, discussing business strategy and growth opportunities [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [4][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [5]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [5].

Core Viewpoint - AVITA Medical, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. EST, and management will be available for one-on-one meetings with registered investors [1]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery [3]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [3]. - In the U.S., AVITA Medical holds exclusive rights to manufacture and market PermeaDerm, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3]. International Market Presence - The RECELL System is approved for promoting skin healing in various applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan (excluding RECELL GO) [4].

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - Inspire Medical Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding the launch of its Inspire V device for obstructive sleep apnea, which resulted in a significant stock price decline [1][5]. Group 1: Lawsuit Details - The class action lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., targets the company and its executives, representing investors who acquired stock between August 6, 2024, and August 4, 2025 [2]. - The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that management made false statements and failed to disclose operational issues that hindered the product launch [2][6]. Group 2: Allegations Against Inspire Medical - The complaint asserts that the transition to the Inspire V device was not as seamless as claimed, with management allegedly providing misleading assurances about the launch's success [3][6]. - Key allegations include poor market demand for the Inspire V, with providers holding excess inventory of the previous device and being hesitant to adopt the new version [8]. - The lawsuit highlights incomplete readiness for the rollout, with essential tasks not being completed, and logistical issues such as training and billing code delays that were not disclosed prior to the product launch [8]. Group 3: Market Reaction - On August 4, 2025, Inspire Medical admitted to an "elongated timeframe" for the Inspire V launch due to undisclosed challenges, leading to a drastic reduction in its 2025 earnings guidance by over 80% [4][5]. - Following this announcement, the company's stock price plummeted by over 32% on high trading volume, prompting the initiation of the investor class action [5].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, exposing patients to serious injury or death [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant risk to patient safety [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. Group 2: Impact on Business Operations - Due to the defects, there is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may need to pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were found to be materially false and misleading, potentially impacting investor confidence and stock performance [3]. Group 3: Legal Proceedings and Shareholder Actions - Shareholders who purchased shares of Baxter during the class period from February 23, 2022, to July 30, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, indicating a structured approach to managing the legal proceedings [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of DexCom, Inc. regarding a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products [1][3]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues related to the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal and financial repercussions for DexCom [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, with a deadline for shareholders to register for the class action set for December 26, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].

Core Insights - Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. complied with federal securities laws following the announcement of a strategic realignment that included discontinuing operations of Tissue Health Plus to improve operating efficiency and reallocate resources to its core surgical business [1] - The announcement led to a decline in Sanara's stock price [1] Company Overview - Sanara MedTech Inc. is publicly traded on NASDAQ under the ticker SMTI [1] - The company is focusing on enhancing its core surgical business by discontinuing less efficient operations [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]